Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2018

View Archived Issues

Nudt15-knockout mouse model shown useful to guide thiopurine dosing in ALL

Atara Biotherapeutics announces initiation of phase III clinical program for tabelecleucel

First patient dosed in phase III trial of tislelizumab in HCC

Cascadian Therapeutics receives pediatric investigation plan waiver from EMA for tucatinib

NexImmune closes series A financing to support initiation of phase I/II trial of AIM ACT

IQGAP1 identified as a potential therapeutic target for AML treatment

Protalix BioTherapeutics reports interim data from phase II study of OPRX-106

FDA grants priority review to Achaogen's plazomicin NDA

Centrexion Therapeutic raises funds for phase III development of CNTX-4975

Five Prime initiates phase I portion of FIGHT trial of FPA-144 in advanced gastric cancer

FDA grants breakthrough therapy designation to Kisqali for premenopausal breast cancer

Achaogen reports topline results from first clinical trial of C-Scape

Tetraphase submits NDA for intravenous eravacycline to treat cIAI

FDA accepts Olinvo NDA

New anti-BCMA-CAR therapy for MM shows promise in preclinical phase

Addex and Indivior sign licensing and collaboration agreement for ADX-71441 to treat addiction

SciFluor Life Sciences patents novel KCNQ2/3 activators

Chinese researchers disclose kappa-opioid receptor agonists

Enanta Pharmaceuticals identifies anti-HBV compounds

Bayer presents novel IRAK-4 inhibitors

New TBK1 and IKK-E inhibitors presented by Bayer

Researchers present novel BALB/c mouse model of PRV infection

Galapagos updates status of cystic fibrosis pipeline

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...